Yeast capping enzymes differ greatly from those of mammalian, both structurally and mechanistically. Yeast-type capping enzyme repressors are therefore candidate antifungal drugs. The 5ʹ-guanine-N7 cap structure of mRNAs are an essential feature of all eukaryotic organisms examined to date and is the first co-transcriptional modification of cellular pre-messenger RNA. Inhibitors of the RNA 5ʹ-triphosphatase in yeast are likely to show fungicidal effects against pathogenic yeast such as Candida. We discovered a new RNA 5ʹ-triphosphatase inhibitor, designated as the kribellosides, by screening metabolites from actinomycetes. Kribellosides belong to the alkyl glyceryl ethers. These novel compounds inhibit the activity of Cet1p (RNA 5ʹ-triphosphatase) from Saccharomyces cerevisiae in vitro with IC 50 s of 5-8 μM and show antifungal activity with MICs ranging from 3.12 to 100 μg ml À1 against S. cerevisiae.
INTRODUCTION

Candidiasis is a fungal infection caused by yeasts of the genus Candida.
Candida is the fourth most common cause of healthcare-associated bloodstream infections. These infections predominantly affect immunocompromised patients, including those with AIDS or cancer, or those who have received organ transplants. Currently, there are only a few systemic antifungal drugs (amphotericin B, flucytosine, several azole drugs and echinocandins) that are available for the treatment of such invasive candidiasis, and not all of these are satisfactory in terms of efficacy, toxicity, their antifungal spectra, or the possibility of drug resistance. There is thus an urgent need for the discovery and development of novel anti-Candida drugs, especially those which have a different mode of action from the currently available drugs.
The 5′ guanine-N7 cap has been found to be an essential feature of all eukaryotic organisms examined to date and is the first co-transcriptional modification of cellular pre-messenger RNA. [1] [2] [3] The first step of cap formation is the removal of γ-phosphate from the RNA 5ʹ-triphosphate end of newly synthesized RNA to generate a diphosphate end by RNA 5ʹ-triphosphatase. Then the GMP moiety of GTP is transferred to the 5ʹ-diphosphate terminus by mRNA guanylyltransferase. After these two consecutive reactions, methylation at the guanine-N7 position catalyzed by mRNA (guanine-N7-) methyltransferase follows. Saccharomyces cerevisiae RNA 5ʹ-triphosphatease (Cet1p) is a member of the divalent cation-dependent triphosphatase family observed in protozoa, eukaryotic viruses and fungi. [4] [5] [6] [7] The X-ray structure of Cet1p revealed the location of two independent active sites within parallel tunnels that are formed by homodimerization of a domain. 5 In yeast such as S. cerevisiae and Candida albicans, the triphosphatase and guanylyltransferase are encoded by distinct genes whose protein products form a noncovalent complex. By contrast, in mammals and plants, the triphosphatase and guanylyltransferase occur in a single-polypeptide chain. Although the guanylyltransferase domain is conserved across evolution, the triphosphatase domain is a metal-independent enzyme that shares structural homology with the cysteine phosphatase superfamily. [8] [9] [10] Thus, the capping enzymes of yeast differ greatly from the capping enzymes of mammals, both structurally and mechanistically, and inhibitors directed against Cet1p may have a fungicidal effect and may be active against clinically important pathogenic yeasts.
During the course of our screening program for new Cet1p inhibitors from metabolites of actinomycetes using a Cet1p enzyme assay system, we found that a strain of Kribbella sp. MI481-42F6 produced new antibiotics, namely kribellosides (Figure 1a,b) . Kribellosides showed moderate RNA 5ʹ-triphosphatase inhibitory activities with moderate anti-yeast activities against S. cerevisiae. In this paper, we describe the isolation, structural determination and biological activity of new RNA 5ʹ-triphosphatase inhibitors, kribellosides.
RESULTS AND DISCUSSION
Taxonomy of the antibiotic-producing strain Strain MI481-42F6 was isolated from a soil sample collected at Nerima-ku, Tokyo, Japan. This strain formed well-branched substrate mycelia and straight to flexuous aerial mycelia. Mature spore chains consisted of 8 to 10 or more spores. Each spore was oval in shape with a smooth surface and was 0.6 × 0.8-0.9 × 1.1 μm in size. The substrate mycelia were pale yellow to pale yellowish brown, whereas aerial mycelia were white. Diaminopimelic acid isomers were of the LL-type. The partial 16 S ribosomal RNA gene sequence (1450 bp) was determined and submitted to the GenBank/EMBL/DDBJ database under accession number LC049957. The gene sequence showed high similarity with those of the genus Kribbella, such as Kribbella aluminosa (JCM 14599 T , 1419/1432 bp, T: Type strain, 99.1%) 11 and K. solani (JCM 12205 T , 1433/1453 bp, 98.6%). 12 These phenotypic and genotypic data suggested that strain MI481-42F6 belongs to the genus Kribbella. Therefore, the strain was tentatively designated as Kribbella sp. MI481-42F6. Detailed taxonomic studies of strain MI481-42F6 are now underway.
Fermentation and isolation of kribellosides
Yeast Cet1p requires magnesium ions for RNA 5′-triphosphatase activity, but has been reported to exert the nucleoside triphosphatase activity in the presence of manganese ions. 13 Therefore, we monitored kribellosides using an in vitro enzyme assay to determine their inhibitory effect on Cet1p nucleoside triphosphatase activity during the purification process. The fermentation of kribellosides was performed by culturing in a 500-ml baffled Erlenmeyer flask containing 110 ml of a producing medium with rotary shaking. The fermentation broth (4 l) was separated into the mycelial cake and the supernatant by centrifugation. The mycelial cake was extracted with MeOH (1 l). The extract, including an active substance, was sequentially extracted with BuOH and a mixture of CHCl 3 -MeOHwater (5:4:6) yielding a brown material (764 mg). The brown material was subjected to chromatography on a low-pressure reversed-phase (C 18 ) column and was developed with MeOH:ammonium carbonate (5 mM) at a ratio of 0:100, 60:40, 80:20 and 100:0. The active fractions were collected and further chromatography was performed by reversed-phase HPLC and developed with acetonitrile/ammonium carbonate (5 mM). The active fractions were collected and concentrated in vacuo to yield 79 mg of pure kribelloside A(1), 83 mg of kribelloside B(2), 26 mg of kribelloside C(3) and 13 mg of kribelloside D(4), respectively, as a colorless powder. Figure 2a .
The NMR data for the kribellosides are summarized in Table 1 . Compound 1 had 1 carbonyl, 2 anomers, 9 oxymethines, 1 sp 3 methine, 4r oxygenated methylenes, 11 methylenes and 2 methyl carbons, as determined by 13 C NMR and DEPT135 spectra. The 1 H 1 H COSY and TOCSY spectra of compound 1 established the five parts shown in Figure 2b . Correlations were observed from the oxymethine of δ H 3.96 (H2) to the oxymethylene at δ H 3.40, 3.83 (H1) and oxymethylene at δ H 3.46, 3.49 (H3), suggesting a glyceryl moiety. The cross peaks observed from the anomer proton at δ H 4.82 (H1ʹ) to oxymethine at δ H 4.07 (H5ʹ) within three oxymethines (δ H 3.51 (H2ʹ), δ H 3.91 (H3ʹ) and δ H 3.71 (H4ʹ)), and from another anomer proton at δ H 5.27 (H1ʹʹ) to the oxymethylene at δ H 3.65 and 3.81 (H6ʹʹ) within four oxmethines (δ H 3.37 (H2ʹʹ), δ H 3.62 (H3ʹʹ), δ H 3.26 (H4ʹʹ) and δ H 3.72 (H5ʹʹ)) suggested two sugar moieties. The remaining portion might be a branched long alkyl chain from the oxymethylene at δ H 3.46 (H4) to the terminal branched dimethyl protons at δ H 0.88 (H17, 18) revealed by the 13-methyl-1-tetradecanol moiety. The connectivities of these parts were established by HMBC spectroscopy, the long-range couplings; H5ʹ/C1ʹ (anomer at δ C 100.9) and carboxyl carbon at δ C 175.2 (C6ʹ) and large proton-proton couplings from H2ʹ to H5ʹ (9.4-9.5 Hz) and ROEs between H3ʹ and H5ʹ revealed an α-glucuronic acid moiety. Long-range couplings, H5ʹʹ/C1ʹʹ (anomer at δ C 101.2) and large couplings from H2ʹʹ to H5ʹʹ (9.5 Hz) and ROEs between H3ʹʹ and H5ʹʹ revealed an α-glucose moiety. The HMBC correlation of H1ʹʹ/C4ʹ established an α-1, 4 bond between glucose and glucuronic acid. Furthermore, long-range connectivities were observed from H1ʹ of the anomer proton of glucuronic acid to glyceryl oxymethylene of H1 and another glyceryl oxymethylene of H3 to H4 of the 13-methyl-1-tetradecanol moiety. Taken together, these results determined the planer structure of 1. The length of the branched alkyl long chain was also established by the ESI/MS in source fragment (m/z 303.2896 (C 18 H 39 O 3 )) as shown in Figure 2a . The structures of compounds 2-4 were determined in the same manner and compared with the data for compound 1. Comparisons of the molecular formula and the 1 H NMR spectra for 1 and 2 described above suggested a lack of glucose moiety in compound 1. Compound 2 was found to possess 1 carbonyl, 1 anomer, 5 oxymethines, 1 sp 3 methine, 3 oxygenated methylenes, 11 methylenes and 2 methyl carbons from the 13 C NMR and DEPT135 spectra. Furthermore, 1D and 2D spectral analyses revealed three parts, namely the glyceryl, 13-methyl-1-tetradecanol and glucuronic acid, that were the same as in compound 1. The difference between compounds 1 and 2 was the higher field shifts from H2ʹ to H5ʹ of glucuronic acid, as observed in the 1 H NMR spectrum. The same in source fragments of ESI/MS spectra for compounds 1 and 2 also supported this structure Novel Cet1p inhibitors from actinomycete M Igarashi et al ( Figure 2a) . Thus, the structure of 2 was determined as shown in Figure 2 . The structures of compounds 3 and 4 were similar to those of 1 and 2 with the exception of one methylene. The 2D analyses of compounds 3 and 4 revealed that they possessed 14-methyl-1-pentadecanol instead of the 13-methyl-1-tetradecanol moiety of compounds 1 and 2. This finding was supported by MS/ MS analysis. The structures of 3 and 4 were determined as shown in Figure 2b .
Stereochemistry of the kribellosides
The absolute chemistry of the C2 of glyceryl ether and the two sugar moieties of the kribellosides was determined by chemical degradations and their derivatives, as shown in Figure 3 . Methanolysis of compound 2 indicated an aglycon and sugar moiety. The reaction mixture was partitioned by a solvent system of n-hexane-MeOH and the n-hexane layer containing aglycon was derivatized to dibenzoate 5. Since the CD spectrum of compound 5 indicated a negative cotton effect, the C2 was determined to be R by the dibenzoate chirality method. 14 The sugar moiety 6 described above was purified from the MeOH layer and identified as methyl-β-D-glucofuranuronic acid γ-lactone by comparing its NMR and CD spectra for the methanolysis product of D-glucuronic acid. Finally, the absolute chemistry of the glucose moiety in 1 was established to be D by the mutarotase-glucose oxidase method. 15 Taking all of these results into account, the absolute chemistry of compounds 1 and 2 are shown in Figure 1 . Compounds 3 and 4 showed the same stereochemistry, as indicated by the physicochemical properties and the NMR data.
Kribellosides are novel compounds that belong to the ether lipids. Ether lipids are known to be ubiquitous in the cell membranes of mammals, 16 marine organisms 17 and archaea. 18 These ether lipids, however, are 1-O-alkyl lipids, whereas the 3-O-alkyl lipids in kribellosides are rare. Therefore, the 1-D-glucuronosyl-sn-glycerol 3-alkyl ether is a unique structure among the ether lipids.
Biological activities of the kribellosides Cet1p inhibitory activity. We examined the inhibitory activity of kribellosides towards S. cerevisiae Cet1p using an in vitro enzyme assay. Since, suramin has been reported to inhibit Cet1p activity, and under our assay conditions it exhibited an IC 50 value similar to that previously reported ( Table 2 ), confirming that our assay conditions with [γ-32 P]triphosphate-ended poly(A) were appropriate for evaluating the inhibitory effect of compounds on triphosphatase activity. Upon treatment with kribelloside A, the hydrolysis of the γ phosphate of triphosphate-ended RNA by Cet1p was inhibited in a dosedependent manner, with an IC 50 of 6.8 μM (Figure 4 and Novel Cet1p inhibitors from actinomycete M Igarashi et al glycerol-alkyl ether has known biological activities, such as lipid hapten activity, 19 antimicrobial activity 20 and the inhibition of cancer metastasis. 21 The 1-D-glucuronosyl-sn-glycerol 3-alkyl ether of kribellosides might be advantageous in its selectivity for the yeast enzyme (Table 2) .
Antimicrobial activity. We evaluated the antimicrobial activity of kribellosides against S. cerevisiae. The anti-yeast activities of kribellosides are shown in Table 3 . Kribellosides exhibited weak antiyeast activities against S. cerevisiae but no antibacterial activity against Gram-positive and Gram-negative bacteria (data not shown).
MATERIALS AND METHODS
General experimental procedures
The optical rotations of the isolated kribellosides were measured using a P-1030 polarimeter (JASCO, Tokyo, Japan). UV spectra were recorded using a U-2800 spectrophotometer (Hitachi High Technologies, Tokyo, Japan) and an FT/IR-4100 Fourier transform infrared spectrometer (JASCO) was employed. The 1 H and 13 C NMR spectra were measured using a JNM-ECA600 spectrometer (JEOL, Tokyo, Japan) at 25°C using tetramethylsilane as an internal reference. The mass spectra were recorded using an LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA). HPLC was detected using an Evaporative Light Scattering Detector (Alltech Associates, Inc., Deerfield, IL, USA).
Taxonomic studies of the producing strain MI481-42F6 23 was amplified by PCR and sequenced. A search for the most closely related sequences was performed using the BLAST algorithm in at the DNA Data Bank of Japan. 
Fermentation of kribellosides
Purification of kribellosides
The fermentation broth (4 l) was separated into the mycelial cake and supernatant by centrifugation. The mycelial cake was extracted with MeOH (1 l). The MeOH solution was removed in vacuo to yield a brown oil. The brown oil, including an active substance, was extracted with BuOH and concentrated in vacuo to give 1.4 g of a brown oil. The 1.4 g of brown oil was extracted with a mixture of CHCl 3 -MeOH-water (5:4:6, 1 l). The upper layer was collected and concentrated in vacuo to dryness yielding a brown material (764 mg). The brown material was subjected to chromatography on a low-pressure reversed-phase (20 × 250 mm, ODS-7515-12 A, Senshu Scientific co., Tokyo, Japan) column developed with MeOH:ammonium carbonate (5 mM) at a ratio of 0:100, 60:40, 80:20 and 100:0. The active fractions were eluted with a ratio of 80:20 and 0:100, and concentrated in vacuo to give a pale brown oil (427 mg). The active material was subjected to further chromatography on reversed-phase HPLC (Capcell Pak UG C18, 30 × 250 mm, Shiseido Co., Ltd., Japan) developed with acetonitrile:ammonium carbonate (5 mM) at Novel Cet1p inhibitors from actinomycete M Igarashi et al 
Analytical procedure
The kribellosides in the fermentation broth and the various purification steps were monitored by reversed-phase HPLC and silica gel TLC. HPLC was performed on a reversed-phase HPLC column (Capcell Pak UG C18, 4.6 × 150 mm, Shiseido, Japan; mobile phase, acetonitrile:ammonium carbonate (5 mM) at a ratio of 45:55; flow rate, 1 ml min − 1 ; column temperature, 25°C; detection, evaporative light scattering detector). Kribellosides A, B, C and D were eluted at 6. (R)-3-((13-methyltetradecyl)oxy)propane-1,2-diyl dibenzoate (5)
Compound 2 (27.0 mg) was dissolved in 3 M of hydrogen chloride-methanol and stirred at 100°C for 14 h. The solution was added to 6 ml of n-hexane and partitioned. The n-hexane layer was dried to yield 10.3 mg of crude aglycon. The methanol layer was dried and re-dissolved in 100 ml of methanol and 1. As an authentic sample of compound 6, 38.0 mg of D-glucuronic acid (Tokyo Chemical Industry Co. Ltd.) was dissolved in 3 M of hydrogen chloride-methanol and stirred at room temperature for 1 h. The reaction mixture was concentrated and the residue was applied for hydrophilic interaction liquid chromatography using the same method described above. 
Mutarotase-glucose oxidase method
Compound 1 (2.3 mg) was dissolved in 1 M HCl (1 ml) and the solution was heated at 85°C for 12 h. The reaction mixture was dried to remove the acid. The residue was dissolved in water and washed with ethylacetate. The aqueous solution was evaporated in vacuo. The residue was dissolved in water (200 μl, 1 × ), and its concentration was halved (2 × ) for the sample solution. Standard D-glucose solutions (100, 500, 1000 and 2000 μg ml − 1 ) and negative controls of the L-glucose solution (1000 μg ml − 1 ) and D-glucuronic acid (1000 μg ml − 1 ) were prepared. The detection of D-glucose was performed using the mutarotase-glucose oxidase method. 18 The sample, standard, negative control and blank solutions (each 20 μl) were added to 3 ml of glucose CII kit enzyme solution at 37°C for 5 min. Then, the reaction mixtures were measured at an absorption of 505 nm. For the standard D-glucose solutions (0, 500, 1000 and 2000 μg ml Screening system for RNA 5ʹ-triphosphatase inhibitor Nucleoside triphosphatase assay. The S. cerevisiae Cet1(201-549)p was expressed in Escherichia coli as an N-terminal hexahistidine (His)-tagged protein and purified by nickel-agarose and ion exchange chromatography. An nucleoside triphosphatase assay with Cet1(201-549)p was performed on a 96-well microplate for initial screening of metabolites from actinomycetes. Aliquots of 40 μl of a reaction mixture containing 50 mM Tris-HCl (pH 7.5), 2 mM MnCl 2 and 8 nM Cet1(201-549)p were dispensed into each well, and then 5 μl of test sample was added to the mixture. After preincubation for 5 min, the reaction was started by adding 5 μl of 400 μM ATP. After incubation at 30°C for 1 h, 75 μl of MicroMolar Phosphate Assay Reagent (ProFoldin, Hudson, MA, USA) was added, and the mixtures were incubated for 5 min. The absorbance at 620 nm was read using a plate reader (ARVOSX 1420 Multilabel counter; PerkinElmer, Waltham, MA, USA).
RNA 5ʹ-triphosphatase assays for Cet1p and hCap
The hCap1 was expressed in E. coli as an N-terminal His-tagged protein and purified by nickel-agarose and ion exchange chromatography. RNA 5ʹ-triphosphatase assays for Cet1p and hCap were performed as described previously with a minor modification. 24, 25 The reaction mixtures for Cet1p containing 50 mM Tris-HCl (pH 7.9), 0.5 mM MgCl 2 , 40 μg of bovine serum albumin and 4 nM Cet1(201-549)p, and for hCap1 containing 50 mM Tris-HCl (pH 7.9), 2 mM DTT, 40 μg of bovine serum albumin and 0.23 nM hCap in a final volume of 10 μl were preincubated with various compounds for 10 min. The reaction was then started by adding 50 nM [γ 32 P]-radiolabeled triphosphateended poly(A). After incubation at 30°C for 10 min, the reaction products were analyzed by polyethyleneimine cellulose TLC with 0.5 M potassium phosphate buffer (pH 3.4). The TLC plate was exposed to an imaging plate and visualized using the phosphorimager Typhoon Variable Model Imager (GE Healthcare, Piscataway, NJ, USA), and the 50% inhibition concentration (IC 50 ) was calculated by four-parameter logistic curve fitting.
Antimicrobial activity
MICs were determined by the standard agar dilution method recommended by the Clinical Laboratory Standards Institute (CLSI) guidelines. 26 Bacteria were incubated on Mueller-Hinton agar (Becton Dickinson) at 37°C for 18 h, whereas yeast were incubated for 42 h.
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